A Phase II, Randomized, Open-label, Multi-centre Study of Weekly APG101 + Reirradiation Versus Reirradiation in the Treatment of Patients With First or Second Progression of Glioblastoma.

Trial Profile

A Phase II, Randomized, Open-label, Multi-centre Study of Weekly APG101 + Reirradiation Versus Reirradiation in the Treatment of Patients With First or Second Progression of Glioblastoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 May 2017

At a glance

  • Drugs Asunercept (Primary)
  • Indications Glioblastoma
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Apogenix
  • Most Recent Events

    • 29 May 2017 According to an Apogenix media release, Asunercept was granted PRIME (PRIority MEdicines) designation by the EMA for the treatment of glioblastoma.
    • 11 Oct 2016 Results assessing levels of CpG2 methylation as predictor of response were presented at the 41st European Society for Medical Oncology Congress
    • 28 Jul 2015 Results published in Apogenix media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top